Durham company bulks up executive suite as cancer therapy development moves forward

About a year-and-a-half after Precision BioSciences inked a cancer therapy deal with Baxalta, valued at up to $1.6 billion, and amid a continued expansion in space and headcount, the Durham-based company has recruited a chief development officer. David Thomson joins the company after working at Shire, where he served as senior vice president and global head of research and nonclinical development. Precision’s portfolio consists of gene therapy and cell therapy products that are based on its gene…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroinfla...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Chang TMS Abstract It is only in the last 20 years that many of the original ideas on artificial cells are being increasingly applied and extended by researchers around the world. Artificial cell has now evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology and other areas. More futu...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Authors: Eckel HE, Bradley PJ Abstract Recent advances in minimal access surgery have shown promise in the treatment of limited hypopharyngeal lesions. In spite of their functionally excellent results in individual patients, it currently remains unlikely that these approaches will gain a more major universal impact on hypopharyngeal cancer care. In advanced stage hypopharyngeal cancer, the use of the traditional radical surgery, such as laryngo-pharyngectomy, is no longer accepted by many patients. In recent years, most would rather opt for less mutilating treatment, preferring a non-surgical option. Patients, fami...
Source: Advances in Oto-Rhino-Laryngology - Category: ENT & OMF Tags: Adv Otorhinolaryngol Source Type: research
Human Gene Therapy,Volume 30, Issue 4, Page 413-428, April 2019.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Volume 47, Issue 1, December 2019, Page 997-1013 .
Source: Artificial Cells, Blood Substitutes, and Biotechnology - Category: Biotechnology Authors: Source Type: research
Publication date: Available online 25 March 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Yanyan Zhu, Yao Meng, Yinan Zhao, Jie Zhu, Hong Xu, Enxia Zhang, Lei Shi, Linying Du, Guoliang Liu, Chuanmin Zhang, Xiaodong Xu, Xiaohui Kang, Yuhong Zhen, Shubiao ZhangAbstractThe toxicology of cationic liposomes was explored to advance clinical trials of liposome-mediated gene therapy through the analysis of a peptide cationic liposome with DOTAP as a positive control. We first investigated the delivery of luciferase siRNA by several peptide liposomes in mice bearing lung cancer A549 cell xenografts. Of these, a catio...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract The toxicology of cationic liposomes was explored to advance clinical trials of liposome-mediated gene therapy through the analysis of a peptide cationic liposome with DOTAP as a positive control. We first investigated the delivery of luciferase siRNA by several peptide liposomes in mice bearing lung cancer A549 cell xenografts. Of these, a cationic liposome (CDO14) was selected for further investigation. CDO14 efficiently mediated IGF-1R-siRNA delivery and inhibited the growth of the A549 cell xenografts. The in vivo toxicity and toxicological mechanisms of the selected liposome were evaluated to assess ...
Source: Colloids and Surfaces - Category: Biotechnology Authors: Tags: Colloids Surf B Biointerfaces Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: American Health | Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Health Management